Medytox

Lyophilized botulinum toxin type A (Hall strain) injection, also sold under export names such as Meditoxin; indicated for benign essential blepharospasm, equinus foot deformity in pediatric cerebral palsy, glabellar lines and post-stroke upper limb spasticity.

Crosslinked hyaluronic acid filler brand with lidocaine, in Light, Deep and Volume versions; in September 2026 Neuramis Volume Lidocaine was approved in China, where it is to be sold under the Fillux brand.

Injectable fat-reduction agent based on cholic acid for moderate to severe submental fat in adults; Korea's 40th domestically approved new drug and the company's first new chemical entity, launched in Korea in late March 2026.

Subsidiary NUMECO runs NEWLUX, a botulinum toxin product developed through technology transfer from Medytox; with Panama's approval in August 2026, NEWLUX is approved in ten countries across Latin America, Asia and Europe.

Operates three manufacturing plants in Korea, at Ochang (Plant 1) and Osong (Plants 2 and 3), and R&D centers in Gwanggyo and Osong.

Launched the fat-reduction injection NUVIJU in Korea in late March 2026; cumulative supply passed 30,000 vials about six months later, in September.

Subsidiary NUMECO received product approval in Panama for its botulinum toxin NEWLUX.

Three Atière hyaluronic acid fillers (Classic, Intensive and Volume) received product approval from Colombia's INVIMA.

The hyaluronic acid filler Neuramis Volume Lidocaine received approval from China's NMPA, giving the company two approved fillers in China alongside Neuramis Deep Lidocaine.